Wednesday, October 05, 2022 7:24:48 PM
Effective immediately prior to the closing of the acquisition, Biohaven completed the spin-off of Biohaven Ltd. (NYSE: BHVN), distributing Biohaven Ltd.’s shares to Biohaven’s shareholders. Biohaven Ltd., a new company that retained Biohaven’s non-CGRP development stage pipeline compounds, holds the Kv7 ion channel activators, glutamate modulation, and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure assets excluded from the Pfizer acquisition. Pfizer, a Biohaven shareholder, received a pro rata portion of Biohaven Ltd.’s shares in the distribution and owns approximately 3% of Biohaven Ltd. Biohaven Ltd. will continue to trade on the New York Stock Exchange under the ticker "BHVN".
New York Yankees and Duke Basketball
Recent BHVN News
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares • PR Newswire (US) • 04/22/2024 08:05:00 PM
- Biohaven Announces Proposed Public Offering of Common Shares • PR Newswire (US) • 04/17/2024 08:05:00 PM
- Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates • PR Newswire (US) • 04/13/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:16:45 PM
- Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments • PR Newswire (US) • 02/29/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:30:54 PM
- Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncolo • PR Newswire (US) • 01/08/2024 12:30:00 PM
- Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/02/2024 12:00:00 PM
- Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting • PR Newswire (US) • 12/01/2023 09:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:15:28 PM
- Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments • PR Newswire (US) • 11/14/2023 09:05:00 PM
- Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® • PR Newswire (US) • 10/16/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 08:05:27 PM
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares • PR Newswire (US) • 10/05/2023 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/04/2023 08:05:45 PM
- Biohaven Announces Pricing of $225 Million Public Offering of Common Shares • PR Newswire (US) • 10/03/2023 03:56:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 01:41:44 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/02/2023 09:09:06 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/02/2023 09:07:23 PM
- BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES • PR Newswire (US) • 10/02/2023 08:36:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 10/02/2023 08:01:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2023 10:58:58 AM
- Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy • PR Newswire (US) • 09/14/2023 11:00:00 AM
- Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies • PR Newswire (US) • 09/05/2023 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2023 09:18:34 PM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM